Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Liver Transplantation for Acute Liver Failure Due to Dengue Fever.

Galante A, Adeyi O, Lau L, Humar A, Galvin Z, Selzner N, Lilly L, Sapisochin G, Bhat M.

Hepatology. 2019 Nov;70(5):1863-1865. doi: 10.1002/hep.30803. Epub 2019 Aug 9. No abstract available.

PMID:
31162847
2.

The Impact of Preexisting and Post-transplant Diabetes Mellitus on Outcomes Following Liver Transplantation.

Aravinthan AD, Fateen W, Doyle AC, Venkatachalapathy SV, Issachar A, Galvin Z, Sapisochin G, Cattral MS, Ghanekar A, McGilvray ID, Selzner M, Grant DR, Selzner N, Lilly LB, Renner EL, Bhat M.

Transplantation. 2019 Dec;103(12):2523-2530. doi: 10.1097/TP.0000000000002757.

PMID:
30985734
3.

Sequential liver and haematopoietic stem cell transplantation in a case of fulminant hepatitis associated liver failure and aplastic anaemia.

Al-Shaibani Z, Kotha S, Lam W, Galvin Z, Lilly L, Lipton JH, Law AD.

Eur J Haematol. 2019 Apr;102(4):375-377. doi: 10.1111/ejh.13213. Epub 2019 Feb 15. Review.

PMID:
30667559
4.

Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.

Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, Zhang W, Kachura J, Beecroft R, Cleary SP, Ghanekar A, Greig PD, McGilvray ID, Selzner M, Cattral MS, Grant DR, Lilly LB, Selzner N, Renner EL, Sherman M, Sapisochin G.

J Hepatol. 2019 May;70(5):866-873. doi: 10.1016/j.jhep.2018.12.027. Epub 2019 Jan 5.

PMID:
30615906
5.

Developing a Simple 3-Day Insulin Delivery Device to Meet the Needs of People With Type 2 Diabetes.

Lilly LC, Mader JK, Warner J.

J Diabetes Sci Technol. 2019 Jan;13(1):11-19. doi: 10.1177/1932296818807223. Epub 2018 Nov 1.

6.

Splenectomy as Flow Modulation Strategy and Risk Factors of De Novo Portal Vein Thrombosis in Adult-to-Adult Living Donor Liver Transplantation.

Linares I, Goldaracena N, Rosales R, Maza L, Kaths M, Kollmann D, Echeverri J, Selzner N, McCluskey SA, Sapisochin G, Lilly LB, Greig P, Bhat M, Ghanekar A, Cattral M, McGilvray I, Grant D, Selzner M.

Liver Transpl. 2018 Sep;24(9):1209-1220. doi: 10.1002/lt.25212.

7.

Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study.

Faisal N, Bilodeau M, Aljudaibi B, Hirch G, Yoshida EM, Hussaini T, Ghali MP, Congly SE, Ma MM, Lilly LB.

Exp Clin Transplant. 2019 Feb;17(1):59-63. doi: 10.6002/ect.2017.0201. Epub 2018 Apr 4.

8.

Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review.

Kuo JC, Lilly LB, Hogg D.

Melanoma Res. 2018 Feb;28(1):61-64. doi: 10.1097/CMR.0000000000000410.

PMID:
29140833
9.

Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study.

Aravinthan AD, Barbas AS, Doyle AC, Tazari M, Sapisochin G, Cattral MS, Ghanekar A, McGilvray ID, Selzner M, Greig PD, Bhat M, Selzner N, Grant DR, Lilly LB, Renner EL.

Transpl Int. 2017 Nov;30(11):1140-1149. doi: 10.1111/tri.13008. Epub 2017 Jul 27.

10.

Early Intervention With Live Donor Liver Transplantation Reduces Resource Utilization in NASH: The Toronto Experience.

Barbas AS, Goldaracena N, Dib MJ, Al-Adra DP, Aravinthan AD, Lilly LB, Renner EL, Selzner N, Bhat M, Cattral MS, Ghanekar A, McGilvray ID, Sapisochin G, Selzner M, Greig PD, Grant DR.

Transplant Direct. 2017 May 10;3(6):e158. doi: 10.1097/TXD.0000000000000674. eCollection 2017 Jun.

11.

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.

Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, Willems B, Vargas H, Kumar P, Brown RS Jr, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault N, Rizzetto M, Müllhaupt B.

Ann Hepatol. 2017 May - Jun;16(3):375-381. doi: 10.5604/16652681.1235480.

12.

Leflunomide for the treatment of trichodysplasia spinulosa in a liver transplant recipient.

Kassar R, Chang J, Chan AW, Lilly LB, Al Habeeb A, Rotstein C.

Transpl Infect Dis. 2017 Aug;19(4). doi: 10.1111/tid.12702. Epub 2017 May 15.

PMID:
28326649
13.

Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma.

Aravinthan AD, Bruni SG, Doyle AC, Thein HH, Goldaracena N, Issachar A, Lilly LB, Selzner N, Bhat M, Sreeharsha B, Selzner M, Ghanekar A, Cattral MS, McGilvray ID, Greig PD, Renner EL, Grant DR, Sapisochin G.

Ann Surg Oncol. 2017 Jul;24(7):1843-1851. doi: 10.1245/s10434-017-5789-3. Epub 2017 Feb 3.

PMID:
28160137
14.

Normothermic ex vivo liver perfusion using steen solution as perfusate for human liver transplantation: First North American results.

Selzner M, Goldaracena N, Echeverri J, Kaths JM, Linares I, Selzner N, Serrick C, Marquez M, Sapisochin G, Renner EL, Bhat M, McGilvray ID, Lilly L, Greig PD, Tsien C, Cattral MS, Ghanekar A, Grant DR.

Liver Transpl. 2016 Nov;22(11):1501-1508. doi: 10.1002/lt.24499.

15.

Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation.

Doyle A, Adeyi O, Khalili K, Fischer S, Dib M, Goldaracena N, Dillon J, Grant D, Cattral M, McGilvray I, Greig P, Ghanekar A, Lilly L, Renner E, Levy G, Selzner N.

Liver Transpl. 2016 Sep;22(9):1295-300. doi: 10.1002/lt.24495. No abstract available.

16.

Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.

Faisal N, Bilodeau M, Aljudaibi B, Hirsch G, Yoshida EM, Hussaini T, Ghali MP, Congly SE, Ma MM, Leonard J, Cooper C, Peltekian K, Renner EL, Lilly LB.

Transplantation. 2016 May;100(5):1059-65. doi: 10.1097/TP.0000000000001126.

PMID:
26950722
17.

Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.

Mumtaz K, Faisal N, Marquez M, Healey A, Lilly LB, Renner EL.

Can J Gastroenterol Hepatol. 2015 Nov-Dec;29(8):417-22. Epub 2015 Jun 15.

18.

Health-related quality of life in long-term survivors of paediatric liver transplantation.

Konidis SV, Hrycko A, Nightingale S, Renner E, Lilly L, Therapondos G, Fu A, Avitzur Y, Ng VL.

Paediatr Child Health. 2015 May;20(4):189-94.

19.

Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis.

Tanaka T, Kurosaki M, Lilly LB, Izumi N, Sherman M.

J Surg Oncol. 2015 Jul;112(1):72-9. doi: 10.1002/jso.23944. Epub 2015 May 29.

PMID:
26032085
20.

Recipient factors associated with having a potential living donor for liver transplantation.

Doyle A, Rabie RN, Mokhtari A, Cattral M, Ghanekar A, Grant D, Greig P, Levy G, Lilly L, McGilvray I, Selzner M, Selzner N, Renner EL.

Liver Transpl. 2015 Jul;21(7):897-903. doi: 10.1002/lt.24148. Epub 2015 Jun 23.

Supplemental Content

Loading ...
Support Center